InspireMD Ltd.

160 articles with InspireMD Ltd.

• InspireMD Reports Third Quarter 2021 Financial Results and Provides Corporate Update

  11/9/2021

  InspireMD Reports Third Quarter 2021 Financial Results and Provides Corporate Update

• InspireMD Announces Publication of 12-Month Results of CGuard™ EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular Interventions

  11/3/2021

  InspireMD, Inc. announced that results from the investigator-initiated SIBERIA randomized clinical trial of CGuard EPS, that evaluated the peri-procedural and 30-day silent brain infarcts associated with the use of its MicroNet™ covered stent versus a conventional “workhorse” open-cell Acculink™ nitinol stent were published this week.

• InspireMD to Report Third Quarter 2021 Financial Results on November 9, 2021 and Provide Corporate Business UpdateEarnings Conference Call to be held Tuesday, November 9, 2021, at 8:30 a.m. ET

  10/26/2021

  InspireMD, Inc., developer of the CGuard™ Embolic Prevention Stent System device for the treatment of Carotid Artery Disease and stroke prevention, announces it will report third quarter 2021 financial results on Tuesday, November 9, 2021, before the market opens.

• InspireMD Announces Strong Second Quarter 2021 Financial Results

  8/10/2021

  InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced financial and operating results as of and for the second quarter ended June 30, 2021.

• InspireMD to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021, and Provide Corporate UpdateEarnings conference call to be held Tuesday, August 10, 2021, at 8:30 a.m. ET

  8/4/2021

  InspireMD, Inc. today announces it will report fiscal first quarter 2021 financial results on Tuesday, August 10, 2021, before the market opens. Management will host a conference call on Tuesday, August 10, at 8:30 a.m. ET to review financial results

• InspireMD to Present at the LD Micro Virtual Invitational Conference on June 9, 2021

  6/2/2021

  InspireMD, Inc. developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by Carotid Artery Disease, announced that Chief Executive Officer Marvin Slosman will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 – 10, 2021.

• InspireMD Announces Warrants Exchange Listing Transfer to NasdaqTickers to be NSPRW and NSPRZ

  5/27/2021

  InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced the Company’s warrants, NSPR.WS and NSPR.WSB, currently traded on the NYSE: American, have been approved for listing on The Nasdaq Capital Market.

• InspireMD Commences Trading on Nasdaq-CMTicker to remain NSPR

  5/21/2021

  TEL AVIV, Israel, May 21, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq-CM: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery Disease (CAD), today announced that the Company’s shares will commence trading on The Nasdaq Capital Market (“Nasdaq-CM”), today, May 21, 2021, under the symbol NSPR. InspireMD CEO Marvin Slosman said, “The trading of our shares on the Nasdaq Capital Market is a yet another very important step in t

• InspireMD to Participate at the Investor Summit Conference and Present to Investors on May 17, 2021

  5/14/2021

  InspireMD, Inc. developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced that management will participate at the Investor Summit Conference on May 17, 2021.

• InspireMD Announces Appointment of Katie Arnold to Board of Directors

  5/12/2021

  InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced it has appointed seasoned marketing executive Kathryn Arnold to its Board of Directors.

• InspireMD Announces First Quarter 2021 Financial Results

  5/11/2021

  InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced financial and operating results for the first quarter ended March 31, 2021.

• InspireMD Announces Stock Exchange Listing Transfer to NasdaqTicker to remain NSPR

  5/10/2021

  InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced the Company’s shares have been approved for listing on The Nasdaq Capital Market.

• InspireMD to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 14, 2021

  5/6/2021

  InspireMD, Inc. developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced that management will participate at the Benzinga Global Small Cap Conference on May 14, 2021.

• InspireMD to Report First Quarter 2021 Financial Results on Tuesday, May 11, 2021 and Provide Corporate UpdateEarnings conference call to be held Tuesday, May 11, 2021 at 8:30 a.m. ET

  5/4/2021

  InspireMD, Inc. (NYSE American: NSPR) (“InspireMD” or the “Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces it will report fiscal first quarter 2021 financial results on Tuesday, May 11, 2021 before the market opens.

• InspireMD Appoints Acclaimed Interventional Cardiologist Kenneth Rosenfield, MD as Chair of its Newly Formed Scientific Advisory Board

  4/29/2021

  InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of the stroke caused by carotid artery disease, announces the formation of its Scientific Advisory Board with its newly appointed chair, acclaimed interventional cardiologist, Kenneth Rosenfield, M.D.

• InspireMD Provides Corporate Update for Shareholders - Apr 19, 2021

  4/19/2021

  InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, provided an update of recent corporate developments.

• InspireMD Announces 1-for-15 Reverse Stock Split

  4/14/2021

  InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced a 1-for-15 reverse split of its common stock, effective as of April 26, 2021.

• InspireMD CEO Marvin Slosman Issues Letter to Fellow Stockholders Urging Support of the Company’s Plans to List its Common Stock on Nasdaq at the Upcoming Special Meeting of Stockholders

  3/22/2021

  InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of the stroke caused by carotid artery disease, issues a message to stockholders from InspireMD CEO, Marvin Slosman regarding the Company’s Special Meeting of Stockholders.

• InspireMD Announces Fourth Quarter and Year-End 2020 Financial ResultsManagement to host investor conference call today, March 9, at 8:30am ET

  3/9/2021

  InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced financial and operating results for the fourth quarter and year ended December 31, 2020.

• InspireMD to Report Fourth Quarter and Year-End 2020 Financial Results on Tuesday, March 9, 2021 and Provide Corporate UpdateEarnings conference call to be held Tuesday, March 9, 2021 at 8:30 a.m. ET

  3/2/2021

  InspireMD, Inc., the developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by carotid artery disease, announces it will report fiscal fourth quarter and year-end 2020 financial results on Tuesday, March 9, 2021 before the market opens.